Progyny, a NYC-based fertility benefits company, secured $10m in Series B extension financing.
Backers included existing investors Kleiner Perkins Caufield and Byers (KPCB), TPG Biotech and SR One.
This new financing will be used to continue to grow the customer base, its national network of fertility specialists, as well as the infrastructure and systems.
Led by David Schlanger, CEO, Progyny combines fertility solutions for employers to offer a comprehensive treatment plan based on medical science and technology to their employees in order to improve outcomes, shorten time to pregnancy and reduce total costs related to fertility.
The company has operations in San Francisco, CA.
FinSMEs
02/05/2017